Accueil   Agenda - News   Toutes les news CEA-Leti breakthrough opens path to new vaccine for HIV using lipid-nanoparticle-delivery technology

CEA-Leti breakthrough opens path to new vaccine for HIV using lipid-nanoparticle-delivery technology

 

GRENOBLE, France – Feb. 27, 2019 – Leti, a research institute of CEA Tech, in collaboration with CEA's Fundamental Research Division, has developed a new vaccine approach for HIV based on engineered lipid nanoparticles that deliver p24 - a viral protein that is key to an HIV vaccine- and optimize the CpG adjuvant's effect.

 

Until now, p24-based vaccines have shown limited effectiveness because of an insufficient immune response to this antigen in HIV patients. Based on its Lipidots® delivery platform, CEA-Leti's new approach improves immunogenicity against the p24 HIV protein by loading it and an immunostimulant agent onto nanostructured lipid carriers (NLCs). This may be a first step for a new HIV vaccine that also would include additional components of the virus.

 

Lire le communiqué de presse complet